Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALP009
MIFTS: 63

Alopecia Areata

Categories: Rare diseases, Skin diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Alopecia Areata

About this section

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 76 53 29 55 6 44 15 73
Cazenave's Vitiligo 53 73
Jonston's Alopecia 53 73
Marginal Alopecia 53 73
Celsus' Vitiligo 53 73
Diffuse Alopecia 53 73
Patchy Alopecia 53 6
Alopecia Celsi 53 73
Circumscribed Alopecia 12
Alopecia Circumscripta 53
Alopecia Cicatrisata 53
Pseudopelade 73
Alopecia 73
Aa 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:986
ICD10 33 L63 L63.9
ICD9CM 35 704.01
MeSH 44 D000506
Sources

Summaries for Alopecia Areata

About this section
NIH Rare Diseases : 53 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. This condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. There is no cure or approved therapy for AA; however, some people find that medications approved for other purposes can help regrow hair.

MalaCards based summary : Alopecia Areata, also known as cazenave's vitiligo, is related to aplastic anemia and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity, and has symptoms including exanthema and pruritus. An important gene associated with Alopecia Areata is AA1 (Alopecia Areata 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Doxorubicin and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and brain, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hypersensitivity reaction type II disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Genetics Home Reference : 25 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.

Wikipedia : 76 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Sources

Related Diseases for Alopecia Areata

About this section

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 31.4 FASLG HLA-A IFNG IL2 TNF
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.3 AIRE CTLA4 IFNG PTPN22
3 chronic mucocutaneous candidiasis 31.1 AIRE IFNG IL2RA
4 temporal arteritis 31.1 IFNG IL1RN PTPN22
5 helicobacter pylori infection 30.7 IFNG IL1RN TNF
6 thyroiditis 30.6 CTLA4 FASLG IL2 PTPN22
7 thymoma 30.6 AIRE CTLA4 IL2
8 herpes zoster 30.5 HLA-A IFNG IL2
9 contact dermatitis 30.5 ICAM1 IFNG IL1A TNF
10 allergic contact dermatitis 30.5 ICAM1 IFNG TNF
11 skin disease 30.4 CXCL10 ICAM1 IFNG TNF
12 arthritis 30.4 IFNG IL1A IL1RN PTPN22 TNF
13 myasthenia gravis 30.3 AIRE CTLA4 IFNG IL2 TNF
14 dermatitis, atopic 30.3 ICAM1 IFNG IL2 IL2RA TNF
15 lichen planus 30.3 GZMB ICAM1 IFNG TNF
16 intermediate uveitis 30.2 IFNG IL2 IL2RA TNF
17 keratoconjunctivitis 30.0 ICAM1 IFNG IL2 TNF
18 cutaneous lupus erythematosus 29.9 GZMB ICAM1 TNF
19 lymphopenia 29.9 FASLG IFNG IL2 IL2RA
20 psoriasis 29.7 CXCL10 ICAM1 IFNG IL1A IL2 PTPN22
21 mycosis fungoides 29.6 CTLA4 CXCL10 GZMB IL2 IL2RA
22 autoimmune disease 29.5 AIRE CTLA4 IFNG IL1RN IL2 IL2RA
23 uveitis 29.1 CTLA4 CXCL10 ICAM1 IFNG IL1A IL2RA
24 graves' disease 29.1 AIRE CTLA4 FASLG ICAM1 IFNG IL2RA
25 celiac disease 1 28.8 CTLA4 GZMB HLA-A IFNG IL2 PTPN22
26 rheumatoid arthritis 28.5 CTLA4 ICAM1 IFNG IL1A IL1RN IL2
27 inflammatory bowel disease 28.3 CTLA4 CXCL10 ICAM1 IFNG IL1A IL1RN
28 systemic lupus erythematosus 27.7 CTLA4 CXCL10 FASLG ICAM1 IFNG IL2
29 diabetes mellitus 26.5 AIRE CTLA4 FASLG GZMB HLA-A IFNG
30 diffuse alopecia areata 12.5
31 amyloidosis aa 12.4
32 alopecia areata 1 12.4
33 helsmoortel-van der aa syndrome 12.3
34 alopecia universalis congenita 12.2
35 alopecia areata 2 12.2
36 adnp syndrome 11.7
37 alopecia totalis 11.7
38 williams-beuren region duplication syndrome 11.5
39 nail disorder, nonsyndromic congenital, 1 11.4
40 alopecia 11.3
41 cutaneous telangiectasia and cancer syndrome, familial 11.1
42 renal nutcracker syndrome 11.1
43 sveinsson chorioretinal atrophy 11.1
44 aarskog-scott syndrome 11.1
45 mental retardation, x-linked, syndromic, claes-jensen type 11.1
46 t-cell receptor-alpha/beta deficiency 11.1
47 bier spots 11.1
48 superior mesenteric artery syndrome 11.0
49 7q11.23 duplication syndrome 11.0
50 clouston syndrome 11.0

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata
Sources

Symptoms & Phenotypes for Alopecia Areata

About this section

UMLS symptoms related to Alopecia Areata:


exanthema, pruritus

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 TNF GZMB ICAM1 IL1A IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 TNF FASLG GZMB ICAM1 IL1A IL2

MGI Mouse Phenotypes related to Alopecia Areata:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.2 IFNG CTLA4 CXCL10 IL1A FASLG IL1RN
2 hematopoietic system MP:0005397 10.18 CXCL10 IL1A FASLG IL1RN IL2 AIRE
3 homeostasis/metabolism MP:0005376 10.13 IFNG CTLA4 CXCL10 IL1A IL1RN FASLG
4 endocrine/exocrine gland MP:0005379 10.1 IFNG CTLA4 FASLG AIRE ICAM1 MC2R
5 digestive/alimentary MP:0005381 10.09 FASLG AIRE ICAM1 IFNG CTLA4 PTPN22
6 immune system MP:0005387 10.07 CXCL10 IL1A FASLG IL1RN IL2 AIRE
7 liver/biliary system MP:0005370 9.7 CTLA4 IFNG FASLG AIRE PTPN22 TNF
8 neoplasm MP:0002006 9.5 IFNG IL1A FASLG AIRE ICAM1 TNF
9 respiratory system MP:0005388 9.23 IFNG CTLA4 FASLG AIRE IL2RA PTPN22
Sources

Drugs & Therapeutics for Alopecia Areata

About this section

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
2
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
3
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
4
Clobetasol Approved, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 32798 5311051
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
6
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
8
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
11
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
12
Hydroxychloroquine Approved Phase 4 118-42-3 3652
13
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
14
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
15
Drospirenone Approved Phase 4 67392-87-4 68873
16
Desogestrel Approved Phase 4 54024-22-5 40973
17 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3 979-32-8
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
19
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
20
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
21
Levonorgestrel Approved, Investigational Phase 4,Phase 3 797-63-7, 17489-40-6 13109
22
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492
23
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
26
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5282380 5311221
27
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
29
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576 3823
30
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
31
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
32
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
33
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
34
Abatacept Approved Phase 4,Phase 2 332348-12-6 10237
35
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
36
Apremilast Approved, Investigational Phase 4,Phase 2,Not Applicable 608141-41-9 11561674
37
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
39
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
40
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
41 tannic acid Approved, Nutraceutical Phase 4,Phase 3
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43 Orange Approved, Nutraceutical Phase 4,Phase 1,Not Applicable
44
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 31703
45 triamcinolone acetonide Phase 4,Phase 2,Not Applicable
46 Prednisolone acetate Phase 4,Not Applicable
47 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
48 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 597)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
3 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
4 Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
5 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
6 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
7 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
8 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
9 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
10 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
11 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
12 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
13 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
14 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
15 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
16 The Vienna Prograf and Endothelial Progenitor Cell Study Completed NCT00182559 Phase 4 Ciclosporin;Tacrolimus
17 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
18 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
19 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
20 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
21 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
22 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
23 Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant Recruiting NCT03353012 Phase 4 Etonogestrel Drug Implant;Levonorgestrel Drug Implant
24 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
25 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
26 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
27 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
28 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
29 Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
30 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Not yet recruiting NCT03422640 Phase 4 Apremilast
31 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
32 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
33 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
34 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
35 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
36 Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
37 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Unknown status NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
38 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
39 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
40 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
41 The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Completed NCT02037191 Phase 3 Methotrexate;Placebo
42 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
43 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
44 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
45 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
46 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
47 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
48 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
49 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
50 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: alopecia areata

Sources

Genetic Tests for Alopecia Areata

About this section

Genetic tests related to Alopecia Areata:

# Genetic test Affiliating Genes
1 Alopecia Areata 29
Sources

Anatomical Context for Alopecia Areata

About this section

MalaCards organs/tissues related to Alopecia Areata:

41
Lung, Breast, Brain, Skin, Ovary, Testes, T Cells
Sources

Publications for Alopecia Areata

About this section

Articles related to Alopecia Areata:

(show top 50) (show all 842)
# Title Authors Year
1
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
2
Alopecia areata. ( 29908825 )
2018
3
Chronological clinicopathological characterization of rapidly progressive alopecia areata resistant to multiple i.v. corticosteroid pulse therapies: An implication for improving the efficacy. ( 29963718 )
2018
4
Alopecia Areata-like Hair Loss Accompanying Toxic Epidermal Necrolysis. ( 29856464 )
2018
5
Coexistence of Dermatomyositis and Alopecia Areata: Insight into Pathogenesis. ( 29854645 )
2018
6
An investigation of vitamin D status in alopecia areata. ( 29869122 )
2018
7
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis. ( 29452121 )
2018
8
Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model. ( 29871523 )
2018
9
Annular Alopecia Areata: A Morphologically Rare Variant. ( 29440858 )
2018
10
Quality of life in mild and severe alopecia areata patients. ( 29872683 )
2018
11
The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population-based retrospective cohort study. ( 29955877 )
2018
12
Alopecia Areata: The Clinical Situation. ( 29273111 )
2018
13
Spontaneous hair regrowth in eight patients with severe alopecia areata. ( 29931820 )
2018
14
Big Data Reveal Insights into Alopecia Areata Comorbidities. ( 29273109 )
2018
15
Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata. ( 29951053 )
2018
16
Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27. ( 29304269 )
2018
17
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. ( 29355049 )
2018
18
Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO). ( 29874239 )
2018
19
Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families. ( 29425723 )
2018
20
Cytokine Targeted Therapeutics forA Alopecia Areata: Lessons fromA Atopic Dermatitis and OtherA Inflammatory Skin Diseases. ( 29273110 )
2018
21
Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata. ( 29979892 )
2018
22
Childhood alopecia areata-Data from the National Alopecia Areata Registry. ( 29334143 )
2018
23
Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. ( 29853767 )
2018
24
Localized atrophy with surrounding hair growth in a case of alopecia areata treated with intralesional steroids, using a needle-less injector. ( 29956680 )
2018
25
When your patient's parent asks: "My child's alopecia areata is not getting better. Should he or she get tested for celiac disease?" ( 29797748 )
2018
26
One of the best treatments for alopecia areata remains unpublished. ( 29878313 )
2018
27
TNF-I+ -308G/A gene polymorphism in bullous pemphigoid and alopecia areata. ( 29843231 )
2018
28
Development of Frontal Fibrosing Alopecia with a History of Alopecia Areata. ( 29440856 )
2018
29
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study. ( 29442292 )
2018
30
Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata. ( 29349811 )
2018
31
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. ( 29754888 )
2018
32
Alopecia areata and the gut-the link opens up for novel therapeutic interventions. ( 29808708 )
2018
33
Do Prolactin and its Receptor Play a Role in Alopecia Areata? ( 29937561 )
2018
34
Nail changes in alopecia areata: an update and review. ( 29318582 )
2018
35
Reply to: "Tofacitinib for the treatment of severe alopecia areata and variants". ( 29332724 )
2018
36
Distinguishing immunohistochemical features of alopecia areata from androgenic alopecia. ( 29790258 )
2018
37
Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata. ( 29323127 )
2018
38
Is there an association of ABO blood groups and Rhesus factor with alopecia areata? ( 29336112 )
2018
39
Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. ( 29679494 )
2018
40
Polymorphism of FAS and FAS Ligand Genes in Alopecia Areata: A Case-control Study in Egyptian Population. ( 29937558 )
2018
41
Color-transition sign: A useful trichoscopic finding for differentiating alopecia areata incognita from telogen effluvium. ( 29512186 )
2018
42
Three Cases of Radiation-induced Temporary Alopecia with Hair Microscopic Examination: "Coudability Hair" Might Not be Specific for Alopecia Areata. ( 29440860 )
2018
43
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
44
Shedding Light on Alopecia Areata in Pediatrics: A Retrospective Analysis of Comorbidities in Children in the National Alopecia Areata Registry. ( 28884897 )
2017
45
Long-term result of hair transplantation for therapy resistant alopecia areata of eyebrows. ( 28731020 )
2017
46
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. ( 28074524 )
2017
47
Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership. ( 28714061 )
2017
48
Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. ( 28801732 )
2017
49
Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: Real-life evaluation. ( 28940756 )
2017
50
Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. ( 28717940 )
2017
Sources

Variations for Alopecia Areata

About this section

ClinVar genetic disease variations for Alopecia Areata:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(1;9;5)(compleX)dn Translocation Likely pathogenic
2 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Likely pathogenic rs1057518972 GRCh38 Chromosome 8, 115418359: 115418359
3 TRPS1 NM_014112.4(TRPS1): c.2794G> A (p.Ala932Thr) single nucleotide variant Likely pathogenic rs1057518972 GRCh37 Chromosome 8, 116430587: 116430587
4 EMILIN2; LPIN2; METTL4; MYL12A; MYL12B; MYOM1; NDC80; SMCHD1; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance GRCh37 Chromosome 18, 1345040: 3479168
Sources

Expression for Alopecia Areata

About this section
Search GEO for disease gene expression data for Alopecia Areata.
Sources

Pathways for Alopecia Areata

About this section

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.99 CTLA4 CXCL10 FASLG HLA-A ICAM1 IFNG
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.35 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
3
PAK Pathway 64
Show member pathways
 13.28 CXCL10 FASLG IL1A IL2 IL2RA PTPN22
4
IL-2 Pathway 64
Show member pathways
 12.77 IFNG IL1A IL2 IL2RA TNF
5
Influenza A 37
Show member pathways
 12.71 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
6
Regulation of IFNA signaling 66
Show member pathways
 12.65 HLA-A IFNG IL1A IL2 IL2RA TNF
7
Allograft rejection 1 37
Show member pathways
 12.6 CTLA4 FASLG GZMB HLA-A ICAM1 IFNG
8
Th17 cell differentiation 37
Show member pathways
 12.43 IFNG IL1A IL2 IL2RA TNF
9
T cell receptor signaling pathway 37
Show member pathways
 12.4 CTLA4 IFNG IL1A IL2 TNF
10
HTLV-I infection 37
12.4 HLA-A ICAM1 IL2 IL2RA TNF
11
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.4 FASLG GZMB HLA-A ICAM1 IFNG IL2
12
Folate Metabolism 1
Show member pathways
 12.31 ICAM1 IFNG IL2 TNF
13
Necroptosis 37
Show member pathways
 12.2 FASLG IFNG IL1A TNF
14
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.2 FASLG GZMB IL1A TNF
15
Bacterial infections in CF airways 22
Show member pathways
 12.18 CXCL10 FASLG IFNG TNF
16
Fluid shear stress and atherosclerosis 37
12.09 ICAM1 IFNG IL1A TNF
17
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.08 ICAM1 IFNG IL1A IL2 IL2RA
18
Spinal Cord Injury 1
12.01 CXCL10 ICAM1 IFNG IL1A IL2 TNF
19
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.99 IFNG IL2 IL2RA TNF
20
Interleukin-4 and 13 signaling 66
11.98 FASLG ICAM1 IL1A TNF
21
IL12-mediated signaling events 1
Show member pathways
 11.93 FASLG GZMB HLA-A IFNG IL2 IL2RA
22
AGE-RAGE signaling pathway in diabetic complications 37
11.86 ICAM1 IL1A TNF
23
Rheumatoid arthritis 37
11.86 CTLA4 ICAM1 IFNG IL1A TNF
24
Hematopoietic cell lineage 37
11.85 IL1A IL2RA TNF
25
NF-kappaB Signaling 4
11.84 CTLA4 CXCL10 FASLG GZMB IFNG IL1RN
26
Innate Lymphoid Cell Differentiation Pathways 65
11.8 GZMB IFNG IL2 IL2RA TNF
27
Glucocorticoid receptor regulatory network 1
11.77 ICAM1 IFNG IL2
28
Dendritic Cells Developmental Lineage Pathway 65
11.73 IFNG IL2 TNF
29
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.68 FASLG IL2 IL2RA
30
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.67 ICAM1 IFNG IL1A IL2 TNF
31
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.61 CTLA4 FASLG IFNG IL2 IL2RA TNF
32
Photodynamic therapy-induced AP-1 survival signaling. 1
11.58 FASLG IFNG IL2 TNF
33
Malaria 37
11.52 ICAM1 IFNG TNF
34
Interleukin-10 signaling 66
11.52 CXCL10 ICAM1 IL1A IL1RN TNF
35
Aryl Hydrocarbon Receptor Pathway 1
11.51 IFNG IL2 TNF
36
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.51 FASLG IFNG IL1A TNF
37
Th2 Differentiation Pathway 65
11.49 IFNG IL2 IL2RA
38
Immune response_Role of integrins in NK cells cytotoxicity 22
11.47 FASLG ICAM1 IFNG
39
African trypanosomiasis 37
11.39 FASLG ICAM1 IFNG TNF
40
Type II interferon signaling (IFNG) 1
11.38 CXCL10 ICAM1 IFNG
41
Inflammatory Response Pathway 1
11.32 IFNG IL2 IL2RA
42
Cytokines and Inflammatory Response 1
11.3 IFNG IL1A IL2 TNF
43
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.29 FASLG GZMB HLA-A IFNG IL2 IL2RA
44
IL12 signaling mediated by STAT4 1
11.23 IFNG IL2 IL2RA
45
LDL Oxidation in Atherogenesis 64
10.9 ICAM1 TNF
Sources

GO Terms for Alopecia Areata

About this section

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CXCL10 FASLG ICAM1 IFNG IL1A IL1RN
2 external side of plasma membrane GO:0009897 9.1 CTLA4 CXCL10 FASLG ICAM1 IL2RA TNF

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.99 CTLA4 HLA-A IL2 IL2RA PTPN22
2 inflammatory response GO:0006954 9.93 CXCL10 IL1A IL1RN IL2RA TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 ICAM1 IL1A PTPN22 TNF
4 response to lipopolysaccharide GO:0032496 9.86 CXCL10 FASLG ICAM1 PTPN22
5 regulation of signaling receptor activity GO:0010469 9.8 CXCL10 FASLG IFNG IL1A IL1RN IL2
6 interferon-gamma-mediated signaling pathway GO:0060333 9.74 HLA-A ICAM1 IFNG
7 humoral immune response GO:0006959 9.72 AIRE IFNG TNF
8 extrinsic apoptotic signaling pathway GO:0097191 9.63 FASLG IFNG TNF
9 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG TNF
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 ICAM1 IFNG TNF
11 response to copper ion GO:0046688 9.6 ICAM1 IL1A
12 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2 IL2RA
13 cytokine-mediated signaling pathway GO:0019221 9.56 CXCL10 FASLG ICAM1 IL1A IL1RN IL2
14 negative regulation of lymphocyte proliferation GO:0050672 9.52 IL2 IL2RA
15 necroptotic signaling pathway GO:0097527 9.51 FASLG TNF
16 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.49 ICAM1 TNF
17 fever generation GO:0001660 9.48 IL1A IL1RN
18 regulation of regulatory T cell differentiation GO:0045589 9.46 CTLA4 IFNG IL2 IL2RA
19 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IFNG TNF
21 immune response GO:0006955 9.36 AIRE CTLA4 CXCL10 FASLG HLA-A IFNG
22 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AIRE CTLA4 CXCL10 FASLG GZMB HLA-A
2 cytokine activity GO:0005125 9.17 CXCL10 FASLG IFNG IL1A IL1RN IL2
Sources

Sources for Alopecia Areata

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....